Related coverage linked through entity extraction aliases.
Aug 18, 2026
Michelle, a mental health therapist, was diagnosed with stage 4 lung cancer and given 24 months to live. Through yoga and meditation, she shifted her mindset and is now thriving six years after diagnosis, with tumors continuing to shrink.
Jul 22, 2026
Semaglutide improves kidney, survival, and quality-of-life outcomes in type 2 diabetes with CKD, per FLOW trial analyses. Benefits were consistent across cardiovascular and severity subgroups, adding eight full-health days per year.
Aug 08, 2026
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Mar 19, 2026
A phase IIa trial found that a single dose of DMT, the active ingredient in ayahuasca, improved depressive symptoms in adults with depression. The small, randomized study showed effects lasting up to three months, with mainly mild adverse effects. Experts call the results promising but preliminary.
Jun 15, 2026
Most advanced cancer patients misunderstand whether their treatment is curative. Honest prognosis discussions improve outcomes without worsening distress, while diagnostic delays persist; pathologist involvement can speed treatment.
Aug 02, 2026
The global CNS therapeutics market was valued at USD 127.29 billion in 2025 and is projected to reach USD 285.72 billion by 2035, driven by demand for Alzheimer’s and Parkinson’s treatments. North America held 45% of the market; neurodegenerative diseases were the largest segment. Private investment and trends toward biologics and AI are shaping the sector.
Aug 01, 2026
A digital mental health program significantly reduced anxiety in breast cancer survivors, with additional coaching helping depression, while a broader review finds eHealth tools improve psychological support in cancer care.
Jul 28, 2026
A study using FAERS and MEPS data found that oral contraceptive side effects such as acne, migraine, anxiety, and depression vary by progestin type. Drospirenone-containing pills had higher reported rates of all four, while acne was also greater with levonorgestrel and norgestimate.
Jul 29, 2026
Kintsugi, a startup developing AI to detect depression and anxiety from voice, is shutting down and open-sourcing its technology due to costly FDA regulatory hurdles. The company’s models analyzed brief speech samples and showed significantly higher depression detection rates than standard questionnaires in a health payer trial. The release aims to empower global research into voice biomarkers for mental healthcare.
Jul 22, 2026
A randomized trial found that remote telehealth genetic services increase uptake of genetic counseling and testing in adult survivors of childhood cancer. At six months, 43% of the telehealth group received services vs. 15% in usual care, with actionable results in 10% of those tested.
Jul 22, 2026
Two new surveys reveal that 24% of U.S. workers stay in unwanted jobs for health insurance, while 19% of adults with tinnitus have cut hours or quit. Debt and chronic illness increase job lock risk; cognitive behavioral therapy shows promise for tinnitus-related work impact.
Jun 25, 2026
Otsuka's ADHD drug centanafadine met the primary endpoint in a Phase 3b trial in adults with comorbid anxiety, with results supporting its efficacy ahead of a July 24, 2026 FDA decision. The FDA has granted priority review to the New Drug Application for the first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). If approved, centanafadine would be a novel treatment option for ADHD in children, adolescents, and adults.
Jun 17, 2026
Two neuroscience studies reveal brain mechanisms behind anxiety and compulsive behavior. One found restoring balance in an amygdala circuit reversed anxiety in mice, while another showed inflammation in the striatum makes behavior more deliberate.
Jun 15, 2026
A genetic framework using Mendelian randomization identified and prioritized drug targets for major depression from over 525,000 cases. The study found drugs targeting genetically supported proteins are 2.6 times more likely to succeed and prioritized 54 repurposing opportunities using existing medications for other conditions.
Jun 13, 2026
University of Florida researchers have established AI Replacement Dysfunction (AIRD), a new clinical model for recognizing and treating stress from AI-driven job insecurity. The framework, published in Cureus, outlines symptoms including anxiety, insomnia, and loss of identity, and proposes screening and treatment approaches for affected workers.
Jun 11, 2026
Vaccine denial and weakened public health measures risk increasing chronic illness, as historical data shows post-infectious conditions follow major outbreaks. Long COVID affects 10-20% of those infected, while historical pandemics led to conditions like encephalitis lethargica with near 50% mortality.
Jun 11, 2026
Advances in precision mental health research include TMS findings published in Nature Molecular Psychiatry showing targeted brain stimulation can address specific depression and anxiety symptoms, the launch of the three-year GlobalMinds NHS genomic study analyzing 49,000 DNA samples, and the new $1 million Wellcome Prize for Mental Health Science.
May 27, 2026
Acromegaly patients face persistent symptoms including fatigue, joint pain, headaches, and brain fog despite biochemical control. Treatment burden and financial barriers remain significant, particularly in sub-Saharan Africa where diagnostic tools and therapies are often inaccessible.
May 25, 2026
A study links sugary drink consumption to anxiety in adolescents, while separate research shows parental substance use patterns strongly influence teen consumption, with authoritative parenting styles offering protective effects.
Apr 27, 2026
A 12-week supervised remote exercise program for patients with metastatic renal cell carcinoma undergoing immunotherapy showed significant improvements in health-related quality of life, fatigue, and symptom burden in a case series of 19 patients.
